Studies of Nuclex effect under cardiovascular disorders, influenza and acute upper respiratory tract infection
by Zenovii Y. Tkachuk; Mykola I. Shved; Olena A. Prokopovych; Pavlo M. Babych
International Journal of Behavioural and Healthcare Research (IJBHR), Vol. 4, No. 1, 2013

Abstract: The obtained results have confirmed the efficacy of Nuclex in terms of normalisation of parameters of coronary reserve, and in terms of elimination of the main signs and symptoms of influenza and acute upper respiratory tract infection (URTI), in particular, normalisation of body temperature, disappearance of headache, catarrhal phenomena, and general fatigue. The decrease in intensity of these signs and symptoms in the study group appeared one to three days earlier than in the control group, and this difference remained significant until the end of treatment. On the 14th day of Nuclex intake influenza A virus H1N1 could not be found by means of PCR in 58.33% of the study group patients, meanwhile in the control group patients the virus was still detectable. The results have clearly demonstrated the significant difference in the treatment efficacy between the control and study groups thus favouring the latter. Nuclex has been proven effective to completely remove the influenza virus from the body.

Online publication date: Sat, 21-Jun-2014

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Behavioural and Healthcare Research (IJBHR):
Login with your Inderscience username and password:

    Username:        Password:         

Forgotten your password?


Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com